86 results about "Very low-density lipoprotein" patented technology

The present invention relates to a method for decreasing elevated serum / plasma LDL-cholesterol levels or LDL-cholesterol levels and CRP levels in a mammal in need thereof. The methods comprises administering an effective amount of a tetracycline formulation. In one embodiment, the tetracycline formulation is a non-antibacterial tetracycline. In another embodiment, the tetracycline formulation is an antibacterial tetracycline at a sub-antibacterial amount.

The present invention provides novel synthetic apolipoprotein E (ApoE)-mimicking peptides wherein the receptor binding domain of apolipoprotein E is covalently linked to 18A, the well characterized lipid-associating model class A amphipathic helical peptide, or a modified version thereof. Such peptides enhance low density lipoprotein (LDL) and very low density lipoprotein (VLDL) binding to and degradation by fibroblast or HepG2 cells. Also provided are possible applications of the synthetic peptides in lowering human plasma LDL / VLDL cholesterol levels, thus inhibiting atherosclerosis. The present invention also relates to synthetic peptides that can improve HDL function and / or exert anti-inflammatory properties.

Cholesterol from Low Density Lipoproteins (LDL-C) is measured directly with a test strip at room temperature using a reagent that takes advantage of the varying surface charge density on LDLs and non-LDLs to selectively make LDL-C available for testing.

The present invention relates to compositions for use in raising or lowering the level of LIPG polypeptide in a patient. Embodiments of the composition include compositions comprising: an anti-sense nucleic acid; a neutralizing antibody; an intracellular binding protein; an inhibitor which inhibits the enzymatic activity of LIPG polypeptide; an inhibitor which inhibits the expression of LIPG gene; a ribozyme; an LIPG polypeptide; an enhancer which increases the enzymatic activity of LIPG polypeptide; or an enhancer which increases the expression of LIPG gene. The invention relates also to methods for using the above compositions.In addition, the invention relates to a method for diagnosing a predisposition to lower cholesterol, a method for determining whether a test compound can inhibit the enzymatic reaction between LIPG polypeptide and HDL cholesterol, and methods for determining whether a test compound can enhance the enzymatic reaction between LIPG polypeptide and LDL or VLDL cholesterol.

A method for quantitating a specific component in lipoproteins contained in a biological sample, for example, HDL (high-density lipoprotein), LDL (low-density lipoprotein) or VLDL (very low-density lipoprotein) by using a commonly employed automatic analyzer without centrifuging or making the reaction liquor cloudy due to complexes or aggregates. Namely, a controlling means, whereby an enzyme reaction can be carried out exclusively for the target component, is introduced into a method for enzymatically assaying a component in a specific lipoprotein fraction in the serum, thereby specifically assaying the component.

The invention relates to an in-vitro diagnostic reagent for a homogeneous method of low-density lipoprotein cholesterol (LDL-C) of serum, wherein the in-vitro diagnostic reagent is capable of being widely applied to the technical field of medicine and biochemistry and is characterized in that the in-vitro diagnosis is carried out by means of a method comprising the following steps of: step one, selectively cracking chyle particles (CM), very low density lipoprotein cholesterol (VLDL-C) and high density lipoprotein cholesterol (HDL-C) within the serum by using a group of surfactant comprising trimethyl-beta-cyclodextrin, ethylene oxide octadecyl amine, poloxamer F88 and Brij-58, then generating hydrogen peroxide (H2O2) during the catalytic reaction of cholesterol esterase (COE) and cholesterol oxidase (COD), and then discomposing the H2O2 by means of a chemiluminescence clearing system of hydrogen peroxide, wherein the LDL-C particles within the serum are still kept perfectly at the moment; step two, reacting the LDL-C by catalyzing with the COE and the COD under the effect of TritonX-100 so as to generate H202, then promoting a chemiluminescence quantitative system to produce chemiluminescence by catalyzing the H2O2 with POD, and quantitating the LDL-C after measuring luminous intensity. The measuring reagent provided by the invention has the advantages that the sensitivity is high, the capacity of resisting disturbance is strong, the purpose for detecting the LDL-C of serum in batch is realized on a microporous plate chemiluminescence apparatus by measuring chemiluminescence intensity, and the reagent is suitable for the application in clinical laboratory.

Reagents, assays, methods, kits, devices, and systems for rapid measurement of cholesterol and cholesterol sub-fractions from a blood sample are provided. Total cholesterol, low density lipoprotein cholesterol, and high density lipoprotein cholesterol can be measured in a single assay using kinetic measurements, under conditions in which cholesterol sub-species are converted to a detectable product at distinct rates. The detectable product is measured at different times after assay initiation. A lipase, cholesterol esterase, cholesterol oxidase and a peroxidase may be used together to produce colored product in amounts directly proportional to the quantity of cholesterol converted. Methods for calculating very-low density lipoprotein cholesterol levels by further including triglyceride measurements are disclosed. Assays may be performed in a single reaction mixture, allowing more accurate and precise cholesterol determinations, including ratios of cholesterol sub-fractions to total cholesterol, at less expense, than would be expected by performing several different assays in different reaction mixtures.

The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding do mains for two different binding sites of LRP6 and compositions and methods of use thereof.

The invention belongs to the fields of membrane surface engineering and bioseparation engineering and aims at providing a method for preparing a low-density lipoprotein affinity adsorption hemodialysis membrane material. The method provided by the invention comprises the following steps: prewashing the hemodialysis membrane material; placing the prewashed hemodialysis membrane material into a plasma processor cavity; introducing inert gas and activated gas until atmosphere ingredients are constant and then carrying out plasma processing; immersing into a heparin solution; adding a coupling agent to carry out an oscillation reaction; carrying out oscillation washing by utilizing a PBS (Phosphate Buffer Solution); and repeatedly washing with clean water and perform filter drying to obtain the low-density lipoprotein affinity adsorption hemodialysis membrane material. In the method provided by the invention, active reaction groups are introduced into by utilizing a constant-pressure and low-temperature plasma activation modification processing method; the reaction is only carried out on the surface of the material, the body performance of the material is not influenced, and simultaneously the method has the characteristics of high efficiency, low cost, low energy consumption, environmental friendliness and the like; the hydrophilia and blood compatibility of the surface of a macromolecule separation membrane material can be greatly improved; and the blockage effect caused by membrane pollution in the hemodialysis course can be effectively reduced.

The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding domains for two different binding sites of LRP6 and compositions and methods of use thereof.

A method of reducing the serum level in a mammal of any one more cholesterol, low density lipoprotein (LDL) cholesterol relative to high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, apolipoprotein B, and triglycerides by the ingestion of a composition containing β-casein A2. A dietary supplement formed by the addition of β-casein to a food or drink for human consumption where the β-casein is comprised of at least 95% β-casein A2, preferably solely β-casein A2.

The invention discloses a preparation method for a calibration matter for calibrating apolipoprotein A1 and apolipoprotein B. The essentials of the technical scheme are as follows: the preparation method comprises the following steps: (1) adding a multi-anionic compound and divalent metal ions into blood serum to carry out pre-treatment; (2) extracting low density lipoprotein (LDL); (3) extracting high density lipoprotein (HDL); (4) mixing protein and base blood serum to prepare the calibration matter; (5) defining the value of the calibration matter. The preparation method has the advantages that the extraction of LDL and HDL components in the blood serum by a multi-anionic compound and divalent metal ion sub-step precipitation method is simplified; the content of the ApoB and the content of the ApoA1 are detected; the calibration matter can be mixed into the blood serum of healthy people according to the needed amount so that the ApoA1 and the ApoB reach the predicated content; the method is simple; a stabilizer and a turbidity-preventing agent are added into the mixed blood serum so that the prepared freeze-dried calibration matter is clarified after being re-dissolved; the stability is good and a base material effect does not exist; the calibration matter is diluted into five different concentrations and can be used for non-linear calibration of determining the ApoA1 and the ApoB on an automatic analyzer.

The present invention relates to the technical field of monoclonal antibodies, particularly to a PCSK9 antagonist. The present invention further provides a method for obtaining the antibodies, uses of the antibodies to reduce the low density lipoprotein (LDL)-cholesterol level, and / or a treatment method for treatment and / or prevention of cardiovascular diseases (including hypercholesterolemia).

The invention belongs to the field of polymers, and particularly relates to a preparation method of an LDL (low density lipoprotein) adsorbent. The LDL adsorbent comprises a polymer carrier serving as a substrate and phosphate groups covalently bonded to the carrier surface, and is prepared as follows: porous epoxy resin with the particle size ranging from 100 mu m to 500 mu m is prepared with a suspension polymerization method and then mixed with anhydrous ethylenediamine, the mixture is heated and stirred, amino resin is obtained and mixed with formaldehyde, phosphorous acid and hydrochloric acid, the mixture is heated and reacts, and the LDL adsorbent is obtained. Polymer microspheres adsorbed by the LDL adsorbent have good removal effect on IgG pathogenic factors.

Ester-form and free-form cholesterols contained in a very-low-density lipoprotein remnant (hereinafter, inclusively referred to as very-low-density lipoprotein remnant cholesterols) are determined. In an aqueous medium containing a sample, a cholesterol ester hydrolase and a cholesterol oxidase or cholesterol dehydrogenase are caused to act specifically on the very-low-density lipoprotein remnant cholesterols in the sample in the presence of a combination of (a) a polyoxyethylene-polyoxyalkylene alkylaryl ether and (b) at least one surfactant selected from the group consisting of a polyoxyethylene / polyoxybutylene condensate, a polyoxyethylene styrenated phenyl ether, and a polyoxyalkylene long-chain alkyl ether.

The invention relates to a health product, which is characterized in that: the health product comprises timnodonic acid, docosahexaenoic acid, hexadecenoic acid, octadecenoic acid, octadecadienoic acid, octadecatrienoic acid, eicosatetraenoic acid and docosapentaenoic acid, wherein the mass summation of the timnodonic acid and the docosahexaenoic acid accounts for 35 to 40 percent of the total mass, and the mass summation of the hexadecenoic acid, the octadecenoic acid, the octadecadienoic acid, the octadecatrienoic acid, the eicosatetraenoic acid and the docosapentaenoic acid accounts for 60 to 75 percent of the total mass. The contents of fish oil extracts EPA and DHA prepared by the method are between 35 and 40 percent; and the deep sea fish oil prepared from the extracts taken as main raw materials has the advantages of having an obvious lipid-reducing effect, diversifying active ingredients, and achieving the effects of inhibiting platelet aggregation, lowering neutral lipid in blood, lowering cholesterol of low density lipoprotein and low density lipoprotein, increasing high density cholesterol, lowering blood viscosity, lowering cholesterol, preventing heart cerebrovascular diseases, reducing arterial pressure, alleviating gout and rheumatoid arthritis, improving the development of the brain and eyes and the like, so that the health product is the best choice of middle and old-aged people.

The invention discloses solid granules capable of lowering blood fat and relaxing bowels and a preparation method of the solid granules. The preparation method comprises the following steps: grinding yellow beans, expanding, adding glucose, NaCl, dried orange peel, red jujubes, artichoke, endives, flaxseeds, bacillus natto, bacillus lacticus, lactobacillus plantarum, lactobacillus rhamnosus and milk powder, performing liquid fermentation twice, concentrating and drying. The solid granules are capable of dissolving thrombi caused by platelet aggregation, reducing lipid thrombi and blood viscosity caused by cholesterol crystal and lipid plaque adhesion, improving blood circulation and intestinal microecological environment and effectively preventing and treating gastrointestinal diseases such as constipation. Meanwhile, the solid granules are also capable of promoting cholesterol excretion, inhibiting endogenous cholesterol synthesis, reducing the content of triglyceride, low-density lipoprotein and very-low-density lipoprotein and increasing the content of high-density serum lipoprotein so as to improve serum lipid, reduce capillary fragility caused by hyperlipidemia and arteriosclerosis, and protect heart and cerebral vessels.

The present invention provides a piece of semiquantitative detecting oxide low-density lipoprotein (OX-LDL) colloid selenium reagent paper, which can capture antigen quantity according to OX-LDL monoclonal antibody to create a relation between color and standard OX-LDL and diagnose that content of OX-LDL in human blood plasma is higher than, lower that or equal to standard OX-LDL quantity in human blood plasma, thus realizing early auxiliary diagnosis to ASCVD. The present invention has the advantages of convenience, quickness, sensitivity, specificity and economic efficiency, rejects specified instruments and equipments and is conveniently taken.

The present invention provides a method of determining whether an individual is at risk for atherosclerosis, comprising the step of: measuring the level of carbamylated LDL in a sample obtained from said individual. Further provided is a method of reducing carbamylation in an individual in need of such reducing, comprising the step of: treating said individual with a monomeric amino acid or another enzymatic or non-enzymatic inhibitor of carbamylation. Also provided is a method of preventing carbamylation in an individual with normal renal function, comprising the step of: treating said individual with a monomeric amino acid. Further provided is a method of treating or preventing atherosclerosis in an individual in need of such reducing, comprising the step of: inhibiting aggregation and / or deposition of carbamylated LDL in said individual.

The invention relates to an OBR (obese receptor) gene and application thereof as goose fat traits genetic markers. Genetic markers related to abdomen fat weight, abdomen fat ratio and blood plasma VLDL (Very Low Density Lipoprotein) concentration in the OBR gene are measured; the existence of polymorphism in the OBR gene in a nucleic acid sample obtained from a goose is measured, wherein the polymorphism is related to the abdomen fat weight, the abdomen fat ratio and the blood plasma VLDL concentration; and the fat traits selection breeding can be carried out on the goose containing the OBR gene in a genome DNA according to the single nucleotide polymorphism of the gene, and an advantageous genotype for reducing the abdomen fat weight, the abdomen fat ratio and the blood plasma VLDL concentration is obtained by the screening. Therefore, the invention has extremely important application value and economic benefit.

A method of inhibiting infection by Flaviviridae viruses including HCV, GBC / HGV, and BVD in addition to VSV and any other virus capable of forming a complex with a lipoprotein strategies: preventing formation of a complex should one form, altering the conformation of such a complex to prevent its interaction with the cell receptor, blocking the cell receptor for the complex using an antibody to the receptor, blocking binding of the lipoprotein complex to the cell receptor using soluble lipoprotein receptor or fragments thereof, or downregulating the LDL receptor activity of the cells.

A method of simultaneously determining the concentrations of cardiovascular risk markers selected from the group consisting of High Density Lipoprotein cholesterol (HDL-C), Low Density Lipoprotein cholesterol (LDL-C), total cholesterol, triglycerides and oxidized LDL using infra-red and / or near infrared light is described.

It is an object of the present invention to provide the method for determining cholesterol in lipoprotein and reagent for determining cholesterol comprising the polymer, and the present invention relates to the reagent for determining cholesterol in lipoproteins such as high-density lipoprotein (HDL), low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) and the determination method using the polymer comprising the following units as constituents:(iv) a polyethylene glycol segment represented by the general formula [1]:—(CH2CH2O)k—  [1](wherein, k represents an integer of 10 to 250);(v) a monomer unit represented by the general formula [2]:(wherein R1 represents a hydrogen atom or C1-C3 alkyl group); and(vi) a monomer unit represented by the general formula [3]:[wherein, R2 represents a hydrogen atom or C1-C3 alkyl group, and R3 represents a group represented by the general formula [4]:—COOR4  [4](wherein, R4 represents an alkyl group, a haloalkyl group or a bornyl group), an alkyl group, an alkoxy group, an aralkyl group or an alkylcarbamoyl group; particularly, in the direct measurement of cholesterols such as HDL, LDL and VLDL contained in the sample, the reagent for determining cholesterol in the presence of said polymer, and the method for determining the concentration of cholesterol in a specific lipoprotein using said reagent for determining cholesterol, and a novel polymer.

The invention discloses a filter membrane for removing low density lipoproteins, and a preparation method thereof. The filter membrane comprises, by weight, 10-25 parts of amphiphilic chitosan, 20-35parts of sulfonic group-modified cellulose acetate, 2-6 parts of poly(2-methacryloyloxyethyl phosphorylcholine) and 1-4 parts of sodium oleate. The filter membrane can effectively reduce the LDL level in the blood, has a good filtering effect on VLDL, TC and TG, has few influences on the level of beneficial proteins in the blood, such as high density lipoproteins, albumins and immunoglobulin IgG,is suitable for purifying the blood of clinical hyperlipidemia patients, can also be applied to the finishing industry of blood products, and can be combined with relevant separation auxiliary devices to recover useful plasma from the waste human plasma that does not meet the blood transfusion standards and produce blood products with high added values.

The invention belongs to the technical field of liquid chromatographic separation, and particularly relates to a rapid and high-purity separation method of human plasma exosome. The method comprises the steps of firstly, removing apoptotic bodies and microvesicles of human plasma through high-speed centrifugation, then loading a sample to an agarose gel small column for pre-separation, and removing most of abundance proteins with relatively small sizes, such as human serum albumin and immune globulin; sequentially carrying out merging and ultrafiltration concentration on the collected fractions, and finally carrying out high performance liquid volume exclusion chromatography separation to realize separation of exosome and interference lipoprotein, thereby finally obtaining the high-purity human plasma exosome fraction. The whole process from plasma pretreatment to exosome fraction obtaining does not exceed two hours. Characterization of immunoblotting proves that the removal rate of high-density lipoprotein (HDL) can reach 95%, and the removal rate of low-density lipoprotein or very low-density lipoprotein (VHDL) can reach 85%.

The invention provides application of oxidized low density lipoprotein for inducing mesenchymal stem cells to differentiate to myocardium-like cells. The experiment shows that when oxidized low density lipoprotein with concentration of 5 micrograms / mL is added into a culture medium of mesenchymal stem cells, BMMSCs have remarkable cell proliferation, the expression of myocardium-like cell specific protein and myocardium cell indicative molecules can be detected, which means that the mesenchymal stem cells are directionally differentiated to myocardium-like cells, and the conversion rate of the myocardium-like cells is as high as 30%.

The invention provides an application of a pharmaceutical composition in the preparation of medicaments for treating obesity, hyperlipidemia or fatty liver, wherein the pharmaceutical composition is prepared by active pharmaceutical ingredients according to the following weight ratios: 100-300 portions of betel nut, 200-600 portions of rhubarb, 200-600 portions of semen pharbitidis, 25-75 portions of fructus gleditsiae abnormalis, 100-300 portions of rhizoma cyperi and 100-200 portions of faeces trogopterori. The pharmaceutical composition has very good treatment or antergic effects to experimental fatty liver caused by high fat diet diseases, can effectively reduce the contents of cholesterol, low density lipoprotein and very low density lipoprotein in serum and increase the content of high density lipoprotein, and has synergistic effect, clear effective substances and controllable quality, without obvious toxic effect, thus being a novel medicament for treating the fatty liver.